Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival

NCT01574170 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT01574170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01574170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Lead sponsor
Institut Claudius Regaud
Phase
Phase 4
Overall status
Completed
Start date
June 18, 2012
Completion date
May 31, 2023
Enrollment
267 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer starting a third line chemotherapy